Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- 6 Japan Drug Makers Net 20% Growth in China Biz Despite COVID-19 Woes
June 1, 2020
- Sumitomo Dainippon to Merge Boston Biomedical, Tolero to Streamline Oncology R&D
June 1, 2020
- Top 4 Wholesalers See Higher Operating Profit Rates in FY2019 Driven by Anticancer Agents, Specialty Products
June 1, 2020
- Chugai Files Patent Litigation against Sawai, Nichi-Iko over Edirol Copies
June 1, 2020
- Takeda Winds Up Development of IBD Drug SHP647
June 1, 2020
- JT, Torii File Topical JAK Inhibitor Corectim for Pediatric Atopic Dermatitis
June 1, 2020
- Otsuka’s Q1 Pharma Sales Surge 13% on Global Brands
May 29, 2020
- Amgen Migraine Med Erenumab Hits Primary Goal in Japan PIII
May 29, 2020
- Bavencio Filed in Japan for Urothelial Carcinoma: Merck Biopharma/Pfizer
May 29, 2020
- Teijin Pharma Files Osteoporosis Drug Abaloparatide in Japan
May 29, 2020
- tella, Cenegenics Begin Clinical Trial of Stem Cell Therapy for COVID-19 in Mexico, Japan Study Planned in Autumn
May 29, 2020
- Sanofi Japan Introduces 2-Week-Rule before Getting Back to Full Operations after COVID-19 Emergency Lift
May 29, 2020
- Drug Makers Exploring “New Normal” in Post-COVID-19; Takeda Plans Major Changes
May 28, 2020
- Towa Voluntarily Recalls Pentasa Generics due to Inadequate Shipment Testing at Contract Manufacturer Nichi-Iko
May 28, 2020
- Japan SGLT2 Inhibitor Market Hits 100 Billion Yen after Weak Start: Jiho Estimate
May 27, 2020
- Fujifilm Eyes FY2020 Trial Launch for Liposome Drug-Keytruda Combo
May 27, 2020
- Shionogi Snaps Up Tetra after PII Alzheimer’s Study Completed
May 27, 2020
- Bayer’s Prostate Cancer Med Nubeqa Now Available in Japan
May 27, 2020
- Japan Pharma Market Tops 10 Trillion Yen for 5th Year Running in FY2019, Keytruda Surges to No.1: IQVIA
May 27, 2020
- Japan Pharma Market Up 0.2% in January-March: IQVIA
May 27, 2020
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…